COMIRNATY is the trade name for the Pfizer–BioNTech mRNA COVID-19 vaccine (BNT162b2), administered intramuscularly for prevention of COVID-19. It was one of the first widely authorized COVID-19 vaccines and has broad global marketing authorizations and prescription status in many jurisdictions. The platform uses mRNA vaccine technology.
BioNTech enters May with first-quarter earnings due May 5 and a May 15 shareholder vote on a capital increase. The company is pushing its oncology pipeline as COVID-19 vaccine sales decline.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging the company's newly approved mNEXSPIKE vaccine uses proprietary mRNA technology without authorization.
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging that Moderna's next-generation COVID-19 vaccine mNEXSPIKE violates its mRNA vaccine design patent.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05977127 |
Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly |
TERMINATED | PHASE2 |
| NCT05858450 |
This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times. |
COMPLETED | |
| NCT05781191 |
Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine |
COMPLETED | |
| NCT05396573 |
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 |
UNKNOWN | PHASE1 |
| NCT05394012 |
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 |
UNKNOWN | PHASE1 |
| NCT05378191 |
Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose |
UNKNOWN | PHASE2 |
| NCT05329220 |
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 |
COMPLETED | PHASE3 |
| NCT05329051 |
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years |
UNKNOWN | PHASE2 |
| NCT05323461 |
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines |
UNKNOWN | PHASE3 |
| NCT05239975 |
A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine |
WITHDRAWN | PHASE2 |
